Core Viewpoint - The company has initiated the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions in China, with plans to recruit approximately 800 participants by September 30, 2025 [1] Company Summary - The company is focused on developing Isuparaglutide α as a treatment for obesity and overweight [1] - The Phase III clinical trial represents a significant step in the product's development pipeline [1] Industry Summary - The clinical trial is part of a broader trend in the pharmaceutical industry towards addressing obesity and related health issues [1] - The recruitment of 800 participants indicates a robust approach to validating the efficacy and safety of the treatment [1]

Core Insights - The company, Silver诺医药-B (02591), has announced the initiation of the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions [1] Company Developments - The clinical trial is set to recruit approximately 800 participants in China [1]

格隆汇9月30日丨银诺医药-B(02591.HK)公布，公司于2025年3月在中国启动公司核心产品(即依苏帕格 鲁肽α)用於治疗肥胖和超重的IIb/III期临床试验。于2025年9月30日，公司已在中国完成核心产品用于治 疗肥胖和超重的III期临床试验的首例患者给药。公司计划就该临床试验招募大约800位参与者。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （股份代號：2591） 自願性公告 有關於中國進行核心產品臨床試驗的最新業務進展 於本公告日期，董事會包括執行董事WANG QINGHUA博士、姜帆女士、徐文潔 女士及黃冰先生；非執行董事HO KYUNG SHIK先生及衡磊先生；及獨立非執行 董事陶武平先生、宋瑞霖博士及陳向榮先生。 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」）作出，以向本公司股東 （「股東」）及有意投資者告知有關本公司近期的業務發展。 誠如本公司日期為2025年8月7日的招股章程所披露，本公司於2025年3月在中華 人民共和國（「中國」）啟動本公司核心產品（即依蘇帕格魯肽α）用於治療肥胖和超 重的IIb/III期臨床試驗。本公司董事（「董事」）會（「董事會」）欣然宣佈，於2025年 9月30日，本公司已 ...

二零二五年中期報告 廣州銀諾醫藥集團股份有限公司 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 股份代號 : 2591 （於中華人民共和國成立的股份有限公司） Guangzhou Innogen Pharmaceutical Group Co., Ltd. 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論與分析 | 5 | | 公司管治及其他資料 | 16 | | 中期簡明綜合損益及其他全面收入表 | 27 | | 中期簡明綜合財務狀況表 | 28 | | 中期簡明綜合權益變動表 | 29 | | 中期簡明綜合現金流量表 | 30 | | 中期簡明綜合財務資料附註 | 32 | | 釋義 | 46 | 2025 年中期報告 2 廣州銀諾醫藥集團股份有限公司 公司資料 執行董事 WANG QINGHUA博士 （董事長） 姜帆女士 徐文潔女士 黃冰先生 非執行董事 HO KYUNG SHIK先生 衡磊先生 獨立非執行董事 陶武平先生 宋瑞霖博士 陳向榮先生 監事 樂建軍先生 李遠鵬博士 邵安娜女士 審計委員會 ...

每经AI快讯，9月16日，港股银诺医药-B(02591.HK)涨超4%，截至发稿，涨4.42%，报46.3港元，成交 额1258.52万港元。 ...

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 4%, currently trading at 46.3 HKD with a transaction volume of 12.5852 million HKD, following the announcement of its core product's market expansion [1] Group 1: Product Development and Approval - The company is actively advancing the global expansion of its core product, Isuparaglutide α [1] - The product received BLA (Biologics License Application) approval for the treatment of Type 2 Diabetes (T2D) in Macau by June 2025 [1] - The first prescription for the core product for T2D treatment was issued at the Huabao Medical Center in Macau on September 12, 2025, marking the official commercialization phase in Macau [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 4%, currently trading at 46.3 HKD with a transaction volume of 12.5852 million HKD, following the announcement of its core product's approval for commercialization in Macau [1] Group 1: Company Developments - The company is actively advancing the global expansion of its core product, Isuparaglutide α [1] - The core product received BLA (Biologics License Application) approval for the treatment of Type 2 Diabetes (T2D) in Macau, expected by June 2025 [1] - The first prescription for the core product in Macau was issued on September 12, 2025, marking the official entry into the commercial sales phase [1]

Core Viewpoint - The company is actively advancing the global expansion of its core product, Isupravaglutide α, which has recently received regulatory approval for the treatment of Type 2 Diabetes (T2D) in Macau [1]. Product Development - The company announced that on September 12, 2025, the first prescription for its core product for T2D was issued at the Huabao Medical Center in Macau, marking the official commercialization phase of the product in the region [1]. - The Biologics License Application (BLA) for the core product was approved in Macau on June 2025, indicating a significant milestone in the product's development [1].

Core Insights - The company is actively advancing the global expansion of its core product, Isupravaglutide α, which is intended for the treatment of Type 2 Diabetes (T2D) [1] - The company received BLA (Biologics License Application) approval for its core product in the Macau Special Administrative Region of the People's Republic of China in June 2025 [1] - The first prescription for the core product for T2D treatment was issued at the Huabao Medical Center in Macau on September 12, 2025, marking the official commercialization phase of the product in Macau [1]